Literature DB >> 19805493

Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity.

Javier Palazuelos1, Tania Aguado, M Ruth Pazos, Boris Julien, Carolina Carrasco, Eva Resel, Onintza Sagredo, Cristina Benito, Julián Romero, Iñigo Azcoitia, Javier Fernández-Ruiz, Manuel Guzmán, Ismael Galve-Roperh.   

Abstract

Cannabinoid-derived drugs are promising agents for the development of novel neuroprotective strategies. Activation of neuronal CB(1) cannabinoid receptors attenuates excitotoxic glutamatergic neurotransmission, triggers prosurvival signalling pathways and palliates motor symptoms in animal models of neurodegenerative disorders. However, in Huntington's disease there is a very early downregulation of CB(1) receptors in striatal neurons that, together with the undesirable psychoactive effects triggered by CB(1) receptor activation, foster the search for alternative pharmacological treatments. Here, we show that CB(2) cannabinoid receptor expression increases in striatal microglia of Huntington's disease transgenic mouse models and patients. Genetic ablation of CB(2) receptors in R6/2 mice, that express human mutant huntingtin exon 1, enhanced microglial activation, aggravated disease symptomatology and reduced mice lifespan. Likewise, induction of striatal excitotoxicity in CB(2) receptor-deficient mice by quinolinic acid administration exacerbated brain oedema, microglial activation, proinflammatory-mediator state and medium-sized spiny neuron degeneration. Moreover, administration of CB(2) receptor-selective agonists to wild-type mice subjected to excitotoxicity reduced neuroinflammation, brain oedema, striatal neuronal loss and motor symptoms. Studies on ganciclovir-induced depletion of astroglial proliferation in transgenic mice expressing thymidine kinase under the control of the glial fibrillary acidic protein promoter excluded the participation of proliferating astroglia in CB(2) receptor-mediated actions. These findings support a pivotal role for CB(2) receptors in attenuating microglial activation and preventing neurodegeneration that may pave the way to new therapeutic strategies for neuroprotection in Huntington's disease as well as in other neurodegenerative disorders with a significant excitotoxic component.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19805493     DOI: 10.1093/brain/awp239

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  137 in total

Review 1.  Neuroinflammation in Huntington's disease.

Authors:  Thomas Möller
Journal:  J Neural Transm (Vienna)       Date:  2010-06-10       Impact factor: 3.575

2.  CB2 cannabinoid receptors promote neural progenitor cell proliferation via mTORC1 signaling.

Authors:  Javier Palazuelos; Zaira Ortega; Javier Díaz-Alonso; Manuel Guzmán; Ismael Galve-Roperh
Journal:  J Biol Chem       Date:  2011-11-18       Impact factor: 5.157

Review 3.  Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?

Authors:  Javier Fernández-Ruiz; Onintza Sagredo; M Ruth Pazos; Concepción García; Roger Pertwee; Raphael Mechoulam; José Martínez-Orgado
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

Review 4.  Potential future neuroprotective therapies for neurodegenerative disorders and stroke.

Authors:  Rawan Tarawneh; James E Galvin
Journal:  Clin Geriatr Med       Date:  2010-02       Impact factor: 3.076

5.  Activation of the Cannabinoid Type 2 Receptor by a Novel Indazole Derivative Normalizes the Survival Pattern of Lymphoblasts from Patients with Late-Onset Alzheimer's Disease.

Authors:  Patricia Del Cerro; Carolina Alquézar; Fernando Bartolomé; Pedro González-Naranjo; Concepción Pérez; Eva Carro; Juan A Páez; Nuria E Campillo; Ángeles Martín-Requero
Journal:  CNS Drugs       Date:  2018-06       Impact factor: 5.749

Review 6.  The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease.

Authors:  Ignacio Munoz-Sanjuan; Gillian P Bates
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

7.  Deletion of Type-2 Cannabinoid Receptor Induces Alzheimer's Disease-Like Tau Pathology and Memory Impairment Through AMPK/GSK3β Pathway.

Authors:  Lin Wang; Bing-Jin Liu; Yun Cao; Wei-Qi Xu; Dong-Sheng Sun; Meng-Zhu Li; Fang-Xiao Shi; Man Li; Qing Tian; Jian-Zhi Wang; Xin-Wen Zhou
Journal:  Mol Neurobiol       Date:  2017-07-17       Impact factor: 5.590

Review 8.  The influence of cannabinoids on generic traits of neurodegeneration.

Authors:  S G Fagan; V A Campbell
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

9.  Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors.

Authors:  Andrea Crotti; Christopher Benner; Bilal E Kerman; David Gosselin; Clotilde Lagier-Tourenne; Chiara Zuccato; Elena Cattaneo; Fred H Gage; Don W Cleveland; Christopher K Glass
Journal:  Nat Neurosci       Date:  2014-03-02       Impact factor: 24.884

10.  Regulatory role of the cannabinoid CB2 receptor in stress-induced neuroinflammation in mice.

Authors:  S Zoppi; J L Madrigal; J R Caso; M S García-Gutiérrez; J Manzanares; J C Leza; B García-Bueno
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.